The fake Eli Lilly account tweeted Nov. 10, and by the time Twitter took it down, the drugmaker lost about $22 billion. As of Nov. 14, a dozen pharmaceutical companies pulled their advertising from the platform, including Merck, Pfizer, Novartis and Eli Lilly, according to advertiser database Pathmatics. All continue to have a Twitter account, though.
The only company to not follow the trend was Germany-based Bayer, which hiked up its spending that week by plugging $480,000 into its Twitter ads, the data showed.
“We continue to monitor developments at Twitter and regularly assess our position,” Bayer told Endpoint News. “We do not release our advertising spend.”
Although drugmakers do not spend much advertising money on the app, Twitter faces a turbulent future amid questions of its power to moderate content.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.